Non-alcoholic fatty liver disease

Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile

Retrieved on: 
Monday, November 13, 2023
Hepatology, SAN, Therapy, AASLD, Liver, Patient, Doctor of Philosophy, Non-alcoholic fatty liver disease, MBA, NASH, Pharmaceutical industry, Boston, Jacob Aligo

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that clinical and nonclinical data for its thyroid hormone receptor-beta (THR-b) drug, ALG-055009, were presented Saturday, November 11th at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, November 10 – 14, 2023. The clinical (#2900-A) and nonclinical (#2461-C) posters for these data can also be found on the “Scientific Presentations & Conferences” section of the Aligos website (www.aligos.com).

Key Points: 
  • The clinical (#2900-A) and nonclinical (#2461-C) posters for these data can also be found on the “Scientific Presentations & Conferences” section of the Aligos website (www.aligos.com).
  • The clinical poster describes a Phase 1 study which evaluated 14 oral daily doses of up to 1.0 mg ALG-055009 solution formulation in hypercholesterolemic subjects.
  • Important highlights include:
    As expected for a thyromimetic, ALG-055009 dose responsively
    The nonclinical poster describes in vitro and in vivo studies which characterize the properties of ALG-055009.
  • “This study, called the HEpatic fat Reduction with ALG-055009 in steatotic Liver Disease (HERALD) study, is on track to initiate dosing in Q1 2024 with topline data, including 12-week MRI-PDFF results, projected in Q4 2024.”

Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023

Retrieved on: 
Friday, November 10, 2023
Safety, Randomness, DSM-IV codes, Efficacy, Therapy, Cohort, AASLD, Cirrhosis, T2D, Patient, EFX, Liver, Risk compensation, Non-alcoholic fatty liver disease, Poster, NASH, Type 2 diabetes, Fibrosis, Pharmaceutical industry, Vaccine, Boston, Åkerö

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced it will present a late-breaking oral presentation and a poster featuring its lead product candidate efruxifermin (EFX) at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023 being held November 10-14 in Boston, MA.

Key Points: 
  • Another analysis of the 36-week SYMMETRY study data showed that the trend for EFX to reverse cirrhosis did not appear to be attributable to concomitant use of GLP-1.
  • The poster describes data from SYMMETRY Cohort D, which evaluated treatment of EFX in combination with a GLP-1 receptor agonist in patients with F1-F3 NASH/MASH and Type 2 diabetes.
  • The poster also includes subgroup analyses from HARMONY showing that improvements in liver histology among F2-F3 NASH/MASH patients associated with EFX treatment with EFX, do not appear to be attributable to concomitant use of GLP-1.
  • We therefore believe that longer periods of treatment with EFX may result in higher rates of fibrosis improvement, including cirrhosis reversal.

Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health

Retrieved on: 
Friday, November 10, 2023
THR, Hepatology, MRE, AASLD, CAP, Hepatitis, Therapy, Incremental cost-effectiveness ratio, ELF, Fibrosis, Priority review, Treatment, Cirrhosis, Lipid, Division, Non-alcoholic fatty liver disease, Fatty liver disease, Atherosclerosis, Abstract, Diabetes, Histology, Biopsy, NDA, Electronic health record, ALT, Artificial intelligence, University, Marie Cassidy, NASH, Intelligence, Research, Disease, LDL, FDA, Radiation Exposure Compensation Act, Medical imaging, Pharmaceutical industry, Boston, Patient, Risk, Gastroenterology

Resmetirom is a liver-directed thyroid hormone receptor (THR)-β agonist oral therapy that is designed to target key underlying causes of NASH.

Key Points: 
  • Resmetirom is a liver-directed thyroid hormone receptor (THR)-β agonist oral therapy that is designed to target key underlying causes of NASH.
  • It is the only investigational therapy for NASH that has achieved both fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial.
  • Resmetirom also reduced levels of LDL cholesterol and other lipids that are associated with heart disease.
  • Resmetirom is an investigational therapy and has not been approved by the FDA or any other regulatory authority.

CN Bio PhysioMimix Organ-on-a-Chip Data Supports Inipharm’s INI-822 for Metabolic Liver Disease Treatment Now in Clinical Testing

Retrieved on: 
Monday, December 4, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Molecule, OOC, Research, DSM-IV codes, Non-alcoholic fatty liver disease, Prevalence, MPS, Hepatology, Patient, Therapy, Drug discovery, NIAB, HSD17B13, NASH, Pharmaceutical industry

The use of in vitro OOC for early evidence of efficacy for INI-822 demonstrates the transformative potential of these models to provide human-relevant data within preclinical programmes.

Key Points: 
  • The use of in vitro OOC for early evidence of efficacy for INI-822 demonstrates the transformative potential of these models to provide human-relevant data within preclinical programmes.
  • Loss-of-function variants of this gene are known to be associated with reduced incidence risk and severity of multiple liver diseases.
  • As part of the recent regulatory submission, CN Bio’s Contract Research Services team utilised the Company’s PhysioMimix OOC Systems and NASH ‘in-a-box' (NIAB) kit to generate critical data to determine compound efficacy.
  • For more information, visit: https://cn-bio.com/
    Inipharm Initiates Dosing in Phase 1 Study of Its Small Molecule Inhibitor of HSD17B13: https://www.businesswire.com/news/home/20231130655005/en/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20231204544807/en/

ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Radiology, Health, Clinical Trials, Medical Devices, Proton, Sale, Magnetic resonance imaging, Hepatology, NAFLD, NDRA, Research, De novo, Food, Endocrinology, International, Magnetic resonance, PIN, Agency, FDA, Non-alcoholic fatty liver disease, Marketing, Liver, De novo synthesis, ATM, NPV, Fatty liver disease, Medical imaging, Video game

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three and nine months ended September 30, 2023 and provides a business update.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three and nine months ended September 30, 2023 and provides a business update.
  • Highlights from the third quarter of 2023 and recent weeks include:
    Shared positive TAEUS clinical data at the Steatotic Liver Disease Summit™ 2023 hosted by the European Association for the Study of the Liver.
  • TAEUS estimates of liver fat fraction were strongly correlated to MRI-PDFF scores with a Pearson correlation coefficient of r=0.87.
  • During the third quarter of 2023 and recent weeks, ENDRA was issued six additional patents, including two in the U.S., two in Europe and two in China.

Boston Pharmaceuticals Announces Positive Phase 2a Data Supporting Once-monthly Dosing With Investigational BOS-580 in NASH and Treatment Effects in Diabetic Subgroups at AASLD The Liver Meeting® 2023

Retrieved on: 
Friday, November 10, 2023
Health, Diabetes, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hepatitis, Hepatology, NAFLD, Liver disease, Insulin resistance, AASLD, Cirrhosis, Doctor of Pharmacy, Risk, Fatty liver disease, Patient, C-peptide, Metabolism, FGF21, Liver injury, Non-alcoholic fatty liver disease, Liver, Biomarker, Glycated hemoglobin, Medication, NASH, Fibrosis, Pharmaceutical industry, Boston

Results support a once-monthly dosing schedule for BOS-580 and the positive effects of treatment for people living with NASH who are at risk for or have type 2 diabetes.

Key Points: 
  • Results support a once-monthly dosing schedule for BOS-580 and the positive effects of treatment for people living with NASH who are at risk for or have type 2 diabetes.
  • These data are being presented on Saturday, Nov. 11, 2023, at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® in Boston.
  • The normal, pre-diabetic and diabetic sub-populations showed very similar reductions (57-66%) in hepatic fat fraction (HFF) after 12 weeks of BOS-580 treatment.
  • “BOS-580 treatment appears promising in maintaining healthy HbA1c levels among patients with phenotypic NASH, irrespective of their concurrent type 2 diabetes status.

NAD-based Anti-Aging Market to Record an Exponential CAGR by 2031 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Thursday, December 14, 2023
Elysium, NAFLD, Research, NAD, Prevalence, Incidence, Antioxidant, Clinical trial, Skin, NMN, Non-alcoholic fatty liver disease, Blood, Elasticity, Ageing, Growth, Patent, Pharmaceutical industry, Renewable energy, Beauty salon

Moreover, the growing demand for different anti-aging skincare products due to the surging geriatric population worldwide is estimated to bloom the market growth during the projected period.

Key Points: 
  • Moreover, the growing demand for different anti-aging skincare products due to the surging geriatric population worldwide is estimated to bloom the market growth during the projected period.
  • Also, the high cost of anti-aging products is limiting the growth of the NAD-based anti-aging market.
  • The NAD-based Anti-Aging Market in North America is expected to hold the largest market share in revenue over the forecast period.
  • Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type

TWIN HEALTH SECURES $50M TO EXPAND ITS GROUNDBREAKING WHOLE BODY DIGITAL TWIN™ TECHNOLOGY AND SERVICE TO REVERSE CHRONIC METABOLIC DISEASE

Retrieved on: 
Wednesday, December 13, 2023
RCT, Sleep, NAFLD, Whole-body vibration, Randomized controlled trial, Type, Temasek, Liver disease, DSM-IV codes, Growth, Metabolic syndrome, Metabolism, Type 2 diabetes, Artificial intelligence, Obesity, Non-alcoholic fatty liver disease, Machine learning, Digital twin, Dyslipidemia, Health, ICONIQ, Digital, CDC, Prediabetes, Weight loss, Medical imaging, Pharmaceutical industry, Starbucks

MOUNTAIN VIEW, Calif., Dec. 13, 2023 /PRNewswire/ -- Twin Health, creators of the Whole Body Digital Twin™ service for reversing, improving, and preventing chronic metabolic diseases, announced securing $50 million in funding to continue expanding its groundbreaking technology and clinical service solutions for more members across the United States.

Key Points: 
  • Through an easy-to-use app, the Whole Body Digital Twin provides members and their Twin Health licensed clinical care team individualized, precise, timely guidance across nutrition, sleep, activity and stress.
  • Twin Health's chronic metabolic disease solution is available today through Twin Health's employer and health plan partners.
  • Twin Health has expanded its reach with strategic partners in the employer and health plan domains, covering over 4 million lives.
  • Notable achievements include completing the world's first randomized controlled trial (RCT) for reversing chronic metabolic disease using digital twin technology.

Red Ginseng's Potential as a Natural Treatment for Improving Withdrawal Symptoms and Dependency due to Drug Addiction Proven Scientifically

Retrieved on: 
Thursday, November 30, 2023
Research, Transitive dependency, Addiction, Culture of Korea, Liver, Mouse, Patient, Drug, Fentanyl, Glutathione, Non-alcoholic fatty liver disease, Morphine, Food science, Pharmaceutical industry, Dietary supplement

Prof. Oh Sei-kwan from Ewha Womans University College of Medicine found that the consumption of red ginseng reduces both physical and psychological dependency induced by drug addiction and greatly improves withdrawal symptoms.

Key Points: 
  • Prof. Oh Sei-kwan from Ewha Womans University College of Medicine found that the consumption of red ginseng reduces both physical and psychological dependency induced by drug addiction and greatly improves withdrawal symptoms.
  • With the global issue of drug addiction becoming increasingly serious, this research result garners even more anticipation.
  • In the absence of a clear cure for the escalating harms of drug addiction, the study on the effects of red ginseng in improving drug dependency is noteworthy.
  • This study scientifically proves the usefulness of red ginseng in treating drug addiction and confirms its potential as a natural treatment for substance dependency, marking an important milestone.

Rosalind Franklin University Innovation and Research Park Welcomes Three Squared Biosciences, Focused on Gut Microbiome Solutions for Chronic Diseases

Retrieved on: 
Tuesday, November 28, 2023
Atherosclerosis, Innovation Place Research Park, Hypertension, NAFLD, Research, Alzheimer's disease, Colorectal cancer, Parkinson's disease, Risk, Disease, Fungal infection, Extrapyramidal system, Intelligence, RFU, Obesity, Non-alcoholic fatty liver disease, Tenant, IBD, MBA, University, Doctor of Philosophy, Innovation, Diabetes, Environment, IRP, Pharmaceutical industry, Management, Science

NORTH CHICAGO, Ill., Nov. 28, 2023 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science announces a new tenant in its Innovation and Research Park: 32 (Three Squared) Biosciences , which builds companies that leverage artificial intelligence to better understand the gut microbiome and uses that knowledge to prevent diseases.

Key Points: 
  • NORTH CHICAGO, Ill., Nov. 28, 2023 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science announces a new tenant in its Innovation and Research Park: 32 (Three Squared) Biosciences , which builds companies that leverage artificial intelligence to better understand the gut microbiome and uses that knowledge to prevent diseases.
  • 32 Biosciences and its subsidiary companies, Gateway Biome and Covira , signed an agreement, effective Nov. 1, for space within the Innovation and Research Park .
  • 32 Biosciences was formed to harness the full potential of Gateway Biome and Covira, spinouts from the University of Chicago.
  • "RFU is committed to expanding collaboration between academic research and the life science industry to improve prevention and treatment of disease."